AIAISci
中文

Commercialization

Commercialization signals

Source facts only. This page is not investment, medical, or legal advice.
clinical updateBiotecheditor reviewed
Rising signal62

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Clinical/translation signal: A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Diagnostics and Biomarkers
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Clinical/translation signal: Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Clinical/translation signal: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Diagnostics and Biomarkers
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Clinical/translation signal: A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Clinical and Regulatory
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Clinical/translation signal: Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Cell and Synthetic Biology
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Clinical/translation signal: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Clinical/translation signal: Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal62

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Clinical/translation signal: Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal60

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Clinical/translation signal: Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Diagnostics and Biomarkers
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context
clinical updateBiotecheditor reviewed
Rising signal60

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Clinical/translation signal: Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Verified by AIScieditor reviewed / 1 evidence source
Organizations
Protein and Drug Design
1 evidence source
Source 1: ClinicalTrials.gov
Open paper workspaceOpen graph context